{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_19216", "batch_size": 200, "batch_pos": 86, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment reports history using neutral language.", "method": "llm_batch", "batch_id": "batch_2_19216", "batch_size": 200, "batch_pos": 66, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "Describes the history of Moderna's research, no moderate verb paired with significant scale/impact.", "method": "llm_batch", "batch_id": "batch_3_19216", "batch_size": 200, "batch_pos": 5, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_19216", "batch_size": 200, "batch_pos": 196, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports history of research, containing no explicit calming cues.", "method": "llm_batch", "batch_id": "batch_5_19216", "batch_size": 200, "batch_pos": 192, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "'small human trial' is not a minimiser + scale contrast.", "method": "llm_batch", "batch_id": "batch_6_19216", "batch_size": 200, "batch_pos": 144, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_19216", "batch_size": 200, "batch_pos": 116, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "regex:CapabilityNoReassurance matched", "method": "regex", "batch_id": "batch_8_19216", "batch_size": 200, "batch_pos": 95, "regex": {"rule": "CapabilityNoReassurance", "span": [15, 22], "captures": []}, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
